Oncotarget Moves Forward in Media and Thyroid Cancer

Oncotarget’s original focus was to use oncology to eliminate or even prevent cancer from taking effects.

Oncotarget had begun in 2010 as a multidisciplinary journal with an initial focus with oncology, the science and the study of overall preventing diseases.

Although, Oncotarget’s methods were initially focused around fighting cancer cells as its primary focus, its methods have since been updated.

One updated method was that Oncotarget had focused around its core values around democratization. In other words, keeping the journal itself open and free to be used.

This demonstration of democratization from Oncotarget is shown through the implementation of Creative Commons Attribution 3.0 License.

Because of the Creative Commons Attribution 3.0 License, it enables researchers to actively share their research papers through the scientific community.

Because of this, more tests and experiments are able to finish more expediently.

Oncotarget was originally focused on the subject of oncology but as the journal began to grow and gain more influence and impact, it had also began to incorporate other adjacent topics such as chromosomes, autophagy, immunology, and other topics of interest.

With the outcome of the published papers being shared more easily, this has allowed for experiments to be conducted much more faster. Listen to Oncotarget podcast on Player.FM.

Progress on The Media Front for Oncotarget

While still growing and gaining influence as an active journal, Oncotarget had also been able to accomplish some of the goals that it had originally set forth before it in the media landscape.

An earlier stated objective that Oncotarget was looking to accomplish outright was increasing the weekly publication rate into a twice-weekly publication rate. This meant that readers of the publication would be receiving two issues both on Tuesday and on Friday.

The outcome would be a two-fold solution.

The first solution that resulted from is that readers are current to the knowledge that is happening in Oncotarget.

The second solution is that hiatuses and gaps are avoided. So, that’s a problem that readers would not have to worry about it.

The weekly-basis journal turning into a twice-weekly publication, Oncotarget had other goals in mind regarding podcasting.

The podcast’s purpose would have been to offer a more digestible for listeners to be able to hear about the breakthroughs from Oncotarget’s journal.

The length of the podcast’s episodes are less than ten minutes, generally, so the episodes are very easy and quick to listen to. This isn’t ignoring the fact that having a podcast makes the episode overall accessible. Learn more at researchgate.net

Listeners can listen to Oncotarget on Stitcher, Player. FM, Soundcloud, and iTunes.

Oncotarget’s Noteworthy Achievements

There are other accomplishments that Oncotarget have been a participant in.

Oncotarget has a impact factor score of 5.168, as evidence of the growing influence that the journal is having.

Another noteworthy accomplishment is that Oncotarget researchers have been able to identify proven new therapeutic strategies to treat thyroid cancer.

Oncotarget is still remaining indexed by most scientific databases such as Journal Citation Reports/Science Edition, Embase, BIOSIS Previews, and Biological Abstracts.

Oncotarget’s accomplishments have been rather noteworthy.

Preventing Diseases with Democratization

This is helped by the fact Oncotarget upholding its democratization principle with the management of their journal.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Eric Lefkofsky: Creating an Innovation in Medicine

Humanity have reached a point where in fatal diseases and pandemics are being eradicated one by one. The joint efforts between physicians and scientists have resulted to the creation of cure for several diseases, and it managed to prolong the life expectancy of humanity. Eric Lefkofsky, a business man, entrepreneur, and a scientist, wanted to invest in the partnership between scientists and physicians so that he can create a computerized weapon that will target pathogens. He would like to create a vast network that will hold thousands and even millions of information from scientists and physicians around the world. He would like to catalog every single pathogen, along with the disease that they carry, and the effects of these diseases to humans. Through the system that he is developing, Eric Lefkofsky is positive that global scientists and physicians would accept the invention that he conceptualized and at least put up some effort to give the project a go signal.

According to Eric Lefkofsky, once he finished the network, scientists and physicians could be more open to each other. He believes that through communication, the world becomes a smaller place, and people tend to meet up with old friends whom they have never seen for long. Eric Lefkofsky added that the reason why he wanted to work with physicians and scientists is that he loves researching and finding out something. Aside from his ventures within the scientific community, Eric Lefkofsky is still busy with his project entitled Tempus. Tempus is an advanced form of technology that is being used to store sensitive and commercial information about a disease. Once the physicians have taken a sample from their patients, these samples are being taken to the system. The system then categorizes all of the information stored with in them. This is very helpful especially for scientists and physicians who are living outside the confines of their comfort zone.

Eric Lefkofsky stated that he is very thankful with the creation of Tempus. He thanked those who have put up their trust on him, and once again, Eric Lefkofsky stated that he will be upgrading the system soon, so that more people can use it without thinking that the machine is difficult.


Mikhail Blagosklonny: Pioneer in the Science of Cancer and Aging

Dr. Mikhail Blagosklonny is a doctor, researcher, editor and professor based in New York. Dr. Blagosklonny’s areas of expertise are cancer and aging. He is highly regarded as a professor and an expert in his field by his peers and students.

His research specifically addresses cancer biology and therapy, and mechanisms of aging and anti-aging drugs. Dr. Blagosklonny’s renown is attributed to his exploration of how treatments can leverage the body’s ability to target and destroy specific cancer cells without harming other healthy cells (which occurs with traditional cancer treatments that target and harm all cells in the body).

Dr. Blagosklonny’s research interests in molecular and cellular biology include oncogenes, tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics and more and learn more about Mikhail.

Dr. Blagosklonny’s fascinating research in progressive cancer treatments has investigated anticancer strategies which include the protection of normal (noncancerous) cells. Specifically, using drug combinations to selectively target cancer cells and shield healthy cells. This research has applications for the treatment of cancer patients, and also for anti-aging medicine. His research has explored the connection between cancer and aging, and why cancer risk increases with age  and more information click here.

Dr. Blagosklonny holds an medical degree in internal medicine and a PhD in experimental medicine from First Pavlov State Medical University of St. Petersburg in Russia. Dr. Blagosklonny has taught as an associate professor at New York Medical College in Valhalla, NY, and at Roswell Park Cancer Institute in Buffalo, NY. He was a senior scientist at Ordway Research Institute Albany, NY and continues his research at Roswell Park Cancer Institute today and Mikhail’s lacrosse camp.

Dr. Blagosklonny has researched and published extensively – authoring over 270 peer-reviewed journal articles, reviews, and book chapters. He is highly involved in both writing and editing medical research, serving on the editorial board of several medical journals:

  • Editor-in-Chief of “Oncotarget”
  • Founding Editor and Editor-in-Chief of “Cell Cycle”
  • Co-Editor and Co-Founder of “Aging”
  • Associate Editor for “Cancer Biology & Therapy”, “Autophagy”, “Cancer Research”, “Cell Death and Differentiation”, “International Journal of Cancer”, “The American Journal of Pathology”, and “PLOS ONE”

Dr. Blagosklonny’s work with online journal Oncotarget expands on his professional goals to make innovative treatments more effective, less harmful, and less expensive. Oncotarget aims to make scientific results rapidly and widely available. The journal publishes articles weekly in the areas of Oncology, Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, and Pharmacology and read full article.

Dr. Blagosklonny’s work are not only making effective cancer treatments more humane, it is also making them more accessible. By reducing the harm and cost of cancer treatment, he aspires to make effective therapies accessible to all patients in need.

More Visit: http://www.phillypurge.com/2017/07/14/oncotarget-mikhail-blagosklonny-rapamycin-incredible-healing-properties/

Clay Siegall And Seattle Genetics’s Grand Plans Of Creating More Drugs

The cancer research community based in Puget Sound region is on the spotlight. That is due to the recent visit of Joe Biden, Vice President of the United States. Seattle Genetics, a cancer drug company is part of what is making the region special with its rapid expansion. Located in Bothell, Seattle Genetics is trying to increase its drugs while widening the use of its initial drug. Additionally, it is on a hiring spree. The move shows the company’s ambitiousness. It also underscores Seattle’s major role as a leading cancer research region.


Seattle Genetics is trying out Adcetris, its only commercialized drug in several cancer treatment scenarios. According to CEO Clay Siegall, presently, the tests are being carried out in over 70 trials against several types of lymphomas. Particularly, the firm is carrying out a phase 3. It is an advanced clinical trial of Adcetris as a leading treatment for Hodgkin lymphoma that has been newly diagnosed or previously untreated. Siegall noted that the trials have had a major impact on the company.


Last year, Adcetris racked up $226 million in sales in the United States and Canada. In 2016, the sales projection for the drug that is mainly used to fight lymphomas is between $255 and $275 in the two countries. Adcetris is sold outside the United States and Canada by Takeda Pharmaceutical, the company’s partner.


Siegall noted that Adcetris is just one drug among the firm’s many. Seattle Genetics has 12 drugs that it is currently developing. This year, the firm wants to get an additional drug into Phase 3 clinical trials. The drug is called 33A. It will be used in treating acute myeloid leukemia. Additionally, Seattle Genetics has a drug for breast cancer as well as two drugs for bladder cancer. Siegall pointed out that in 2016, they will disseminate considerable information on the three drugs.


In the meantime, the firm is on a hiring spree. This year, it plans to add 100 professionals in the United States and nearly 20 for its Switzerland office. So far, the company has over 800 employees.


About Clay Siegall

Clay Siegall is the president and CEO of Seattle Genetics. He co-founded the cancer drug company in 1998. Siegall also serves as the company’s board chairman. He is a trained scientist that majored on targeted cancer therapies. Siegall established the firm on a strong foundation of rigorous research, scientific innovation, and drug development practices. He has led the company to become a leader in the development of antibody-drug conjugates for cancer treatment.

Original Sources: